In another vein, previous studies with the ATP-competitive inhibitor CX-4945 showed that protein kinase CK2 could regulate p53 protein turnover and PI3K/AKT signaling in AML cells [43,50]. The gene discussed is TP53; the disease is acute myeloid leukemia.